Biotech: The Craziest Sector
Investopedia calls biotech “simultaneously one of the most exciting and one of the
riskiest corners of the stock market.” As you can see from our Top 50 article, and
from the Vantage 2019 preview in this issue, both points of view can be credibly
Nearly two thirds of the Top 50 experienced an increase. Revenues as a whole were
up by 9%. The biotech industry remains one of the most volatile. That leaves a lot of
room for both investor interest and investor anxiety, and why this area is on a roller-coaster ride.
It should come as no surprise that the top ten on our list comprise 73% of the revenue in the group, and
continue to increase at a healthy rate. They are solid companies with good management. We also have to
look at what’s attracting the most attention. Cell therapy, CAR-T therapies and Crispr gene editing are
among the headliners.
The FDA continues to be bullish on biotech. Its current attitude has been to fast-track promising therapies, which of course will bring investors to the table.
While our Top 50 reaches only until the end of 2018, subsequent news requires mention. While the last
quarter of 2018 saw predictions of a bear market in biotech, by January there was a renewed interest in
the sector, led by the $74 billion mega-deal of Bristol-Myers Squibb (BMY) and Celgene, and the market
is reporting other significant potential biotech mergers and acquisitions.
And always, please keep the feedback coming. It all goes to making the magazine better for all of us.
Cari Kraft, Publisher
Click to download to your mobile device of choice
CLICK HERE TO GET
TOP 50 BIOTECH COMPANIES